Skip to main content
Premium Trial:

Request an Annual Quote

For Fees

The US Senate has passed both a bill to allow the US Food and Drug Administration to recoup fees to finance its drug and medical device review activities as well as one that expands patients' access to experimental treatments, the New York Times reports.

The Senate passed the FDA Reauthorization Act in a 94-to-1 vote, Reuters adds. The bill would renew the agency's ability to collect user fees from drug companies. These fees make up about a quarter of FDA's budget, the Times notes. The bill also includes provisions to prevent price increases of decades-old drugs that lack competition, speed the review of generic drugs, and to boost cancer drugs for children, the Times says.

Reuters adds that the bill passed the House of Representatives last month, and the Times says President Donald Trump is expected to sign it.

The Senate also passed the Right to Try Act that would allow terminally ill patients increased access to experimental therapies and protect doctors and companies that provide the drugs. Reuters notes that the House has not passed this bill.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.